InsiderTradr

4basebio PLC (4BB.L)

LSE · GBp · Healthcare · Biotechnology

£530.00 (+0.00%) as of

Key statistics

Market cap
82.07M
Forward P/E
-6.24
EPS (TTM)
-1.16
Dividend yield
0.00%
52-week range
420.00 – 820.00
Beta
0.81
Revenue (TTM)
781k
Profit margin
0.00%
Analyst target
£1,225.00
Volume
328.00

About 4basebio PLC

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is headquartered in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Cambridge, United Kingdom
Employees
140

4basebio.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks